Meeting
2021 ASCO Annual Meeting
Efficacy finding cohort of a cancer peptide vaccine, TAS0313, in treating recurrent glioblastoma.
Authors
Yoshiki Arakawa
Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan
Yoshiki Arakawa , Yoshiko Okita , Yoshitaka Narita
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
JapicCTI-183824
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2038)
DOI
10.1200/JCO.2021.39.15_suppl.2038
Abstract #
2038
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Design and initiation of an adaptive, randomized, controlled study of berubicin, a topoisomerase 2 poison that crosses the blood brain barrier (BBB), for the treatment of recurrent glioblastoma multiforme (GBM) after first-line therapy.
First Author: Sandra Silberman
Poster
2022 ASCO Annual Meeting
EO2401, a novel microbiome-derived therapeutic vaccine for patients with recurrent glioblastoma: ROSALIE study.
First Author: Wolfgang Wick
Poster
2014 ASCO Annual Meeting
Safety and immunologic efficacy of personalized multiple HLA class I-restricted peptide vaccines for breast cancer patients in the adjuvant setting.
First Author: Uhi Toh
Poster
2023 ASCO Annual Meeting
EO2401 (E) peptide immunotherapy + nivolumab (N) +/- bevacizumab (B) in recurrent glioblastoma (GB): EOGBM1-18/ROSALIE.
First Author: Wolfgang Wick